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Dr. Dorothy Horstmann, epidemiologist, virologist, clinician, and educator, was the first
woman appointed as a professor at the Yale School of Medicine. Horstmann made signifi-
cant contributions to the fields of public health and virology, her most notable being the
demonstration that poliovirus reached the central nervous system via the bloodstream, up-
setting conventional wisdom and paving the way for polio vaccines. In 1961, she was ap-
pointed a professor at Yale School of Medicine, and in 1969, she became the first woman
at Yale to receive an endowed chair, which was named in honor of her mentor, Dr. John
Rodman Paul. In this review, the major scientific contributions of Dr. Dorothy Horstmann will
be highlighted from her more than 50-year tenure at Yale School of Medicine.
introduction
Dorothy  Millicent  Horstmann  was
born in Spokane, Washington, on July 2,
1911 [1]. She spent much of her youth in
San Francisco and earned her undergradu-
ate degree from the University of Califor-
nia, Berkeley in 1936. Four years later,
Horstmann graduated from the University
of California, San Francisco with a medical
degree. Concurrent with Horstmann’s de-
velopment as a scientist and clinician was
the development of polio as one of the most
feared diseases in the United States. Al-
though rare in the late 19th century, polio
epidemics began to occur more frequently
in the early 1900s. One of the worst epi-
demics took place in 1916, when a polio
epidemic  tore  through  the  northeastern
United States [2], claiming nearly 6,000
lives and leaving more than 27,000 people
paralyzed. This epidemic first put polio in
the  national  spotlight,  and  by  the  time
Horstmann came to Yale, polio was quickly
becoming the nation’s most feared disease
[3].
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was first identified by the Viennese scien-
tists Karl Landsteiner and Erwin Popper in
1908 [4]. Ninety percent of people infected
by poliovirus never develop symptoms. The
majority of those who develop symptoms
have a mild illness, while approximately 10
percent develop the most severe form of the
disease: acute flaccid paralysis [5]. Paralysis
occurs when the virus invades the central
nervous system and destroys motor neurons,
which are required for muscle contraction
[6].  This  nervous  tissue  damage  usually
leads to a temporary paralysis. However, in
the case of more severe damage, the patient
permanently  loses  the  function  of  those
muscles. Permanent paralysis most often oc-
curs in the muscles that control the legs or
breathing. The latter led to death unless the
patient  was  placed  in  an  iron  lung.  The
prospect of an iron lung, a pressurized metal
chamber that served as a respirator for the
patient, was one of the most dreaded conse-
quences of polio infection.
HorStMAnn’S EArLY YEArS At
YALE
Yale  hired  Horstmann  (Figure  1)  in
1942 as a Commonwealth Fellow in Inter-
nal Medicine under the tutelage of Dr. John
Rodman Paul. In 1931, together with Dr.
James Trask and other Yale scientists, Paul
started the Yale Poliomyelitis Study Unit to
respond to the ever-increasing epidemics of
polio [7]. Paul was a pioneer in the field of
epidemiology and formed a new discipline
called clinical epidemiology, which focused
on  “exploring  the  multiple  factors  con-
tributing to the occurrence of disease in in-
dividuals  and  in  population  groups”  [8].
Horstmann applied these techniques in her
studies of poliovirus.
In the early 1940s, leaders in the field
of polio research, such as Simon Flexner at
the Rockefeller Institute in New York City,
believed that poliovirus infected the brain by
traveling through the nerves in the nasal pas-
sage [9]. The reason for Flexner’s beliefs
about polio pathogenesis and transmission
was due to the experimental model used to
study polio. Flexner and his colleagues used
virus isolated from brain tissue of monkeys
that exhibit paralysis to infect other groups
of monkeys via intracerebral inoculation.
The  passaging  of  the  poliovirus  only
through brain inoculation led to the adapta-
tion of a lab strain of the virus that only in-
fected nervous tissue. Furthermore, when
Flexner  would  later  attempt  to  inoculate
monkeys orally with the lab strain of the
virus, no disease symptoms would develop.
Flexner’s findings falsely led scientists to
believe for decades that poliovirus could
only replicate in nervous tissue and could
not cause central nervous system infection
as a result of oral delivery of the virus [10].
Horstmann and her colleagues believed in a
different picture of transmission and would
soon defy the conventional wisdom that po-
liovirus  exclusively  infected  the  nervous
system.
During 1943 and 1944, Horstmann and
the Yale Study Unit were asked to investi-
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Figure 1. Dorothy Horstmann is pictured in her
office at the Epidemiology and Public Health
Laboratory Building. Though Horstmann’s fac-
ulty appointment was in pediatrics and epi-
demiology, her office and laboratory were both
located in the epidemiology department. Photo
courtesy of Dr. I George Miller. gate five different outbreaks of polio in the
United  States.  Those  occurred  in  New
Haven, Connecticut, Chicago, Illinois, and
Bakersfield, California, in 1943, and in and
around Hickory, North Carolina, and New
York City in 1944. The findings were pub-
lished in a series of four articles in 1946 [11-
14].  Horstmann  and  her  colleagues
systematically  determined  whether  virus
could be recovered from pharyngeal swabs,
oropharyngeal washings, feces, and blood
from patients and their contacts during the
outbreaks. These studies were unique in sev-
eral ways. The approach of taking samples
from multiple sites over multiple days from
a single patient had never been done in such
a comprehensive manner. This was impor-
tant to determine how long the virus per-
sisted in the pharyngeal and gastrointestinal
tract and to determine the relative impor-
tance of each site during infection. The ma-
jority of fecal samples were positive for
poliovirus over multiple weeks while viral
recovery from the pharyngeal tract was tran-
sient and infrequent. These results, along
with the findings of other scientists, pointed
to the gastrointestinal tract, and not the nasal
passage,  as  playing  an  important  role  in
polio  pathogenesis.  One  puzzle  that  re-
mained was how the virus transited from the
gastrointestinal tract to the brain if the virus
was acquired by way of ingestion and not in-
halation.  
HorStMAnn’S SiGniFicAnt
BrEAKtHrouGH in PoLio 
PAtHoGEnESiS
During  the  New  Haven  outbreak  in
1943, Horstmann collected blood from all
111 suspected polio cases admitted to Yale-
New Haven Hospital. Only one sample out
of the 111 tested positive for poliovirus [11].
Although the significance of this finding
seemed minimal since it was such a rare
event, there were unique characteristics of
this one case that caught Horstmann’s atten-
tion. In the majority of the 110 other cases
admitted to the hospital, blood was drawn
after polio symptoms such as paralysis had
developed. The one positive case, a 9-year-
old girl living in New Haven, presented to
the hospital, and blood was drawn within six
hours of developing mild disease. The girl
never developed paralysis. This difference
in timing between the cases led Horstmann
to look closer at the period between infec-
tion with the virus and onset of symptoms.
Her results would fundamentally change the
conventional wisdom of polio transmission
and pathogenesis.
To test whether the bloodstream played
a role in polio pathogenesis, Horstmann per-
formed a series of experiments in monkeys
and chimpanzees. First, the animals were fed
poliovirus orally to follow what Horstmann
and others previously had shown to be the
natural route of infection. Then blood sam-
ples from these animals were taken each day
for 7 days after infection to determine if and
when poliovirus could be found in the blood.
The results were surprising. Poliovirus was
detected in the blood within 4 to 6 days of
the feedings before onset of paralysis in the
majority of the animals tested [15]. These
findings were later independently confirmed
by David Bodian at John Hopkins Univer-
sity [16]. The results indicated why previous
scientists, and Horstmann herself, had so
often failed to detect virus in the blood-
stream: They had waited too long. Previ-
ously, blood samples were taken after the
onset  of  more  severe  disease  symptoms,
such as paralysis. By this time, polio-spe-
cific antibodies already would have been cir-
culating  in  the  bloodstream,  effectively
neutralizing the virus. Therefore, at the time
of the blood draw, no virus would be de-
tectable in the blood. Horstmann went on
further to show that virus could be recovered
from the blood of contacts of polio patients
who later developed disease or remained
asymptomatic [17]. These discoveries over-
turned the general consensus in the scientific
community  that  poliovirus  solely  infects
nervous tissue and paved the path to the cur-
rent model of poliovirus transmission and
pathogenesis. 
Dr. John Enders, who won the Nobel
Prize for his work on developing a tissue
culture method to replicate poliovirus, cred-
ited Horstmann with shaking “the widely
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nerve cells” [18]. Enders further went on to
say  about  Horstmann’s  discovery  that
“everyone  was  relieved  to  find  that  po-
liomyelitis was not an exceptionally bizarre
disease, but similar to others.” Further praise
for Horstmann’s discovery was communi-
cated in a private letter to Horstmann from
Yale’s distinguished historian of medicine,
John F. Fulton, MD, DPhil, who proclaimed:
“This disclosure is as exciting as anything
that  has  happened  in  the  Yale  Medical
School since I first came here in 1930 and is
a tremendous credit to your industry and sci-
entific imagination. . . . It is also medical his-
tory” [19]. Horstmann’s discovery also had
important implications for the development
of a polio vaccine.
HorStMAnn’S diScoVErY LEAdS
to A PoLio VAccinE
Horstmann’s  discovery  provided  the
specific anatomic sites in which to stop po-
liovirus ― the blood and gastrointestinal
tract. Vaccines against viruses typically use
an attenuated form or components of the
pathogen to reproduce the quality of the im-
mune response that is elicited upon natural
infection. An oral polio vaccine that closely
mimics the natural route of infection of the
virus could be used to elicit antibodies in the
blood and gastrointestinal tract that would
later block poliovirus infection. Horstmann
and Paul’s seroepidemiologic surveys fur-
ther supported the use of an oral polio vac-
cine. In a study conducted in Casablanca,
Morocco, from 1947 to 1953, polio cases
were compared between European and na-
tive Moroccan populations [20]. The study
illustrated some striking differences in polio
epidemiology between the two groups. The
European group had 20-fold higher rates of
polio and the majority of cases were more
than 2 years old. When the native Moroccan
population was surveyed for polio antibod-
ies in the blood, the majority of children had
antibodies by 2 years of age, and these anti-
bodies  persisted  in  the  population  for
decades. Exposure to poliovirus infection as
infants seemed to elicit antibody production
that protected the Moroccan children from
disease later in life. The results of these sero-
epidemiologic studies by Horstmann and
others supported the development of a vac-
cine that elicited antibodies in the blood and
gastrointestinal tract. 
At the same time Horstmann and others
published their results pointing toward an
oral polio vaccine as the best option to pro-
tect against polio infection, testing began in
the United States with an inactivated polio
vaccine. That vaccine, developed by Jonas
Salk, was a form of killed poliovirus deliv-
ered by subcutaneous injection [21]. The
vaccine did generate protective polio-spe-
cific antibodies in the blood in children and
adults but not in the gastrointestinal tract.
Furthermore, the inactivated polio vaccine
required the use of sterile needles, which are
not readily available in resource poor set-
tings, while an oral polio vaccine did not re-
quire needles. Therefore, Horstmann and her
colleagues supported the further develop-
ment of an oral polio vaccine. Though sev-
eral  groups  were  developing  oral  polio
vaccines, the vaccine created by Albert Sabin
soon reached the forefront. Sabin was a cli-
nician and virologist who had been in the
vanguard of polio research for decades. His
vaccine induced the best antibody response
while having the least neuropathogenic ef-
fects in monkeys and chimpanzees [22,23].
Since vaccination with the inactivated polio
vaccine had already begun in the United
States, scientists looked outside the country
to test the oral polio vaccine in humans.
Massive trials of the oral polio vaccine
were started in the Soviet Union in 1956. Al-
though Soviet scientists reported favorable
results with the oral polio vaccine, much of
the world was skeptical of the Soviets’ find-
ings and called for outside validation of the
their results. Without this validation, no rec-
ommendations would be given for use of the
oral polio vaccine. The World Health Or-
ganization (WHO†) asked Horstmann, by
now a well-respected scientist in the polio
field, to validate the Soviets’ results. By the
time Horstmann arrived in the Soviet Union
in 1959, close to 15 million children had re-
ceived  the  oral  polio  vaccine  in  Russia,
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spent 6 weeks evaluating the Soviet scien-
tists’ results. Her subsequent favorable re-
port to the WHO about the vaccine trials in
the Soviet Union led the way to worldwide
acceptance of the oral polio vaccine and li-
censing of the vaccine in the United States in
1961 [24]. Not long after the licensing and
widespread use of oral polio vaccine in the
United  States,  the  last  person-to-person
transmission of wild poliovirus in the United
States was detected in 1979 [25].
HorStMAnn AS A cLiniciAn And
EducAtor
Horstmann’s experience studying polio,
which primarily attacks the young, naturally
led her to change her focus from internal
medicine  to  pediatrics  mid-career. When
Horstmann described her experiences work-
ing on polio epidemics, she said, “It had a
dramatic immediacy. When you deal with an
epidemic you realize it’s an urgent thing.
There was so much to be learned” [19].
Horstmann’s later research in polio went on
to further characterize the immune response
elicited from the oral polio vaccine in vac-
cinated persons and contacts in the United
States and worldwide [26-28]. Horstmann
also became an expert in many other child-
hood and congenital viral diseases and pub-
lished several research articles about the
clinical  epidemiology  of  Rubella,  Cox-
sackie, and Echo viruses. Horstmann’s re-
search on Rubella virus was instrumental in
the licensing of the Rubella vaccine in chil-
dren in the United States in 1969 [29]. 
Horstmann continued her work at Yale
with a joint appointment in both Pediatrics
and Epidemiology. Horstmann was the first
woman to be appointed a tenured professor
in 1961 in the Yale School of Medicine and
was the first woman at Yale to receive an en-
dowed chair. The endowed chair was in honor
of her colleague and mentor, Dr. John Rod-
man Paul. In addition to Horstmann’s sub-
stantial  contributions  to  science,  she  also
made important educational contributions. In
Horstmann’s Festschrift, published in 1982 in
honor of her retirement, her colleague, Dr.
Robert Berliner, noted her imprint on clinical
education  at  Yale  School  of  Medicine.
Berliner pointed out that Horstmann “en-
larged the scope of infectious disease to em-
brace its public health aspects. She has also
been a staunch supporter of the integration of
diagnostic microbiology and virology into the
practice and teaching of infectious disease”
[30]. In addition to Horstmann’s accomplish-
ments as a clinician, scientist, and teacher, she
contributed significantly to her professional
community. Horstmann served as a president
of the Infectious Disease Society of America
(Figure 2) and was elected to the National
Academy of Sciences in 1975. 
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Figure 2. Dorothy
Horstmann and Albert






of the society in 1975.
Horstmann is pictured
here giving an award




tesy of Dr. I George
Miller.In Horstmann’s honor, an annual lec-
tureship has been established at Yale in Pe-
diatric  Infectious  Diseases  and
Epidemiology.  Several  notable  scientists
have  spoken  as  part  of  the  Dorothy
Horstmann Lecture since its inception in
1991. These scientists include Nobel Prize
winners, vaccine pioneers, and leaders in the
fields of immunology and infectious dis-
eases. Ten years after the establishment of
the  lecture,  Dorothy  Horstmann  passed
away in New Haven, Connecticut. In the
words of her colleague Berliner, there was
no one “more highly regarded as a person
and as a university citizen” among the fac-
ulty than Dorothy Horstmann [30]. Her con-
tributions  as  a  polio  pioneer,  scientist,
clinician, and educator have left an indelible
stamp on the Yale School of Medicine.  
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